Comparing Insmed (NASDAQ:INSM) & DiaMedica Therapeutics (NASDAQ:DMAC)

DiaMedica Therapeutics (NASDAQ:DMAC) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Risk & Volatility

DiaMedica Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Insmed has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Institutional and Insider Ownership

10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares DiaMedica Therapeutics and Insmed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77 million	($0.72)	-8.88
Insmed	$1.14 billion	22.76	-$1.28 billion	($4.11)	-28.84

DiaMedica Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DiaMedica Therapeutics and Insmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Insmed	-76.94%	-123.94%	-44.30%

Analyst Recommendations

This is a summary of recent ratings and target prices for DiaMedica Therapeutics and Insmed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1	0	4	0	2.60
Insmed	1	0	22	2	3.00

DiaMedica Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 87.79%. Insmed has a consensus target price of $205.52, suggesting a potential upside of 73.38%. Given DiaMedica Therapeutics’ higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Insmed.

Summary

DiaMedica Therapeutics beats Insmed on 9 of the 14 factors compared between the two stocks.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.